Investigation of mast cell-stimulating factors using blood from subjects with chronic spontaneous urticaria

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030230097

Enrollment

Registered

2023-05-26

Start date

2023-06-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic spontaneous urticaria

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic spontaneous urticaria (CSU) 1)Patients who were diagnosed as chronic spontaneous urticaria following the criteria of the Japanese Dermatological Association Guidelines. 2)Patients who were not administered any medications other than antihistamines and adjunctive therapies as defined by the guidelines of the Japanese Dermatological Association, with symptom of urticaria at least 4 times a week for more than 4 weeks and persisting for more than 4 weeks, moderate and severe CSU patients (UAS7 >= 16, ISS7 >= 6 and HSS7 >= 6), and who had never received omalizumab. 3)Patients aged between 16 and 70 years at the time of consent,regardless of gender Healthy control subjects 1)Subjects aged between 16 and 70 years at the time of consent,regardless of gender 2)Subjects who are not diagnosed as chronic spontaneous urticaria following the criteria of the Japanese Dermatological Association

Exclusion criteria

Exclusion criteria: Patients with chronic spontaneous urticaria who were administered corticosteroids or immunosuppressive drugs within 4 weeks prior to the study

Design outcomes

Primary

Measure	Time frame
The amount of MRGPRX2 levels in plasma-derived extracellular vesicles	—

Contacts

Public ContactKoremasa Hayama

Nihon University Itabashi Hospital

ML-KPNU_CSU@mb.kyorin-pharm.co.jp+81-3-3972-8111

Outcome results